DLB subjects also show decreases in Cerebrospinal (CSF) biofluid markers that measure amyloid-beta and tau proteins, indicating that amyloid and tau metabolism may be disrupted in DLB as well (van Steenoven et al., 2019; Bolsewig et al., 2024; Vrillon et al., 2024). The gene discussed is MAPT; the disease is Lewy body dementia.